|
|
Time |
Source |
|
Announcement
|
|
| 17 Mar 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs |
| 16 Mar 2021 |
11:40 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche Annual General Meeting 2021 |
| |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) |
| 15 Mar 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample |
| 11 Mar 2021 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia |
| 08 Mar 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer |
| 05 Mar 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition |
| 26 Feb 2021 |
5:30 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany |
| |
12:12 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 |
| |
11:30 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older |
| 25 Feb 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine |
| 12 Feb 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients |
| 08 Feb 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients |
| 04 Feb 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche reports solid results in 2020 |
| 01 Feb 2021 |
4:25 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection |
| 25 Jan 2021 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche renews partnership with Sysmex to deliver haematology testing solutions |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration |
| 18 Jan 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy |
| 12 Jan 2021 |
10:55 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer |
| 11 Jan 2021 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years |
| 05 Jan 2021 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer |
| 23 Dec 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer |
| 21 Dec 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness |
| 15 Dec 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark |
| 14 Dec 2020 |
8:20 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis |
| 11 Dec 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients |
| 10 Dec 2020 |
12:50 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 |
| 09 Dec 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials |
| 08 Dec 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers |
| 07 Dec 2020 |
6:04 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New follow-up phase III data reinforce the long-term benefit of Roche’s Hemlibra for people with haemophilia A |
| 05 Dec 2020 |
5:45 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia |
| 02 Dec 2020 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies |
| 01 Dec 2020 |
5:07 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA approves Xolair® (omalizumab) for adults with nasal polyps |
| 24 Nov 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person |
| 16 Nov 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh time |
| 13 Nov 2020 |
4:00 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza |
| |
1:00 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer |
| 05 Nov 2020 |
2:00 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting |
| 02 Nov 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer |
| 29 Oct 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer |
| 22 Oct 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients |
| 19 Oct 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia |
| 15 Oct 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic |
| 13 Oct 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients |
| 28 Sep 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) |
| 19 Sep 2020 |
3:20 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 |
| 18 Sep 2020 |
2:20 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer |
| |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia |
| 17 Sep 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 |
| 16 Sep 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer |
| 11 Sep 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis |
| 10 Sep 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) |
| 09 Sep 2020 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) |